Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of act… Read more
Adocia (ADOC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 14.997x
Based on the latest financial reports, Adocia (ADOC) has a cash flow conversion efficiency ratio of 14.997x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-9.25 Million) by net assets (€-617.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Adocia - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Adocia's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Adocia Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adocia ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Champion Microelectronic Corp
TW:3257
|
0.079x |
|
De Licacy Industrial Co Ltd
TW:1464
|
0.054x |
|
Powercell Sweden
ST:PCELL
|
0.310x |
|
NIVIKA FASTIGHETER AB
F:Y5R
|
N/A |
|
Briscoe Group Australasia Ltd
AU:BGP
|
0.076x |
|
Taiwan Optical Platform Co Ltd
TW:6464
|
0.038x |
|
HUSCOMPAGNIET A/S DK 5
F:HCE
|
N/A |
|
Bookook Securities Co Ltd
KO:001275
|
-0.102x |
Annual Cash Flow Conversion Efficiency for Adocia (2010–2024)
The table below shows the annual cash flow conversion efficiency of Adocia from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-3.09 Million | €-15.61 Million | 5.054x | +605.94% |
| 2023-12-31 | €-6.91 Million | €-4.95 Million | 0.716x | -38.08% |
| 2022-12-31 | €-12.97 Million | €-14.99 Million | 1.156x | -16.95% |
| 2021-12-31 | €-13.81 Million | €-19.23 Million | 1.392x | +140.35% |
| 2020-12-31 | €6.33 Million | €-21.85 Million | -3.450x | -902.03% |
| 2019-12-31 | €28.04 Million | €-9.65 Million | -0.344x | -350.07% |
| 2018-12-31 | €45.85 Million | €6.31 Million | 0.138x | +122.83% |
| 2017-12-31 | €36.86 Million | €-22.23 Million | -0.603x | -96.29% |
| 2016-12-31 | €42.76 Million | €-13.14 Million | -0.307x | -132.56% |
| 2015-12-31 | €47.05 Million | €-6.22 Million | -0.132x | -101.08% |
| 2014-12-31 | €2.50 Million | €30.56 Million | 12.200x | +2261.78% |
| 2013-12-31 | €19.13 Million | €-10.80 Million | -0.564x | -1514.13% |
| 2012-12-31 | €23.03 Million | €919.00K | 0.040x | +102.78% |
| 2011-12-31 | €4.33 Million | €-6.22 Million | -1.436x | -209.61% |
| 2010-12-31 | €10.69 Million | €-4.96 Million | -0.464x | -- |